AT-02, a humanized IgG1-peptide fusion reagent that potently binds cardiac amyloid
Aug. 30, 2023
At the recent ESC Congress, researchers from University of Tennessee and Attralus Inc. presented preclinical data on the novel pan-amyloid-binding peptide fusion immunoglobulin AT-02, which is being developed for the treatment of amyloidosis.
